Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Serena Di CosimoJosé Manuel Pérez-GarcíaMeritxell BelletFlorence DalencMiguel J Gil GilManuel Ruiz-BorregoJoaquín GaviláElena AguirrePeter SchmidFrederik MarméJoseph GligorovAndreas SchneeweissJoan AlbanellPilar ZamoraDuncan WheatleyEduardo Martínez de DueñasKepa AmillanoEileen ShimizuMiguel Sampayo-CorderoJavier CortésAntonio Llombart-CussacPublished in: Breast (Edinburgh, Scotland) (2024)
PPI use may reduce palbociclib capsule toxicity, dose modifications, and clinical activity in HR+/HER2- ABC.